Revolution Medicines (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 4,175 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Stephen Michael Kelsey sold 4,175 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the transaction, the insider directly owned 291,876 shares in the company, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Trading Up 3.3%

Shares of RVMD opened at $162.99 on Friday. The firm has a 50-day moving average price of $145.72 and a 200 day moving average price of $112.99. Revolution Medicines, Inc. has a 12-month low of $34.00 and a 12-month high of $166.50. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $34.65 billion, a P/E ratio of -23.05 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period last year, the business posted ($1.13) EPS. Sell-side analysts forecast that Revolution Medicines, Inc. will post -7.94 EPS for the current year.

Institutional Trading of Revolution Medicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RVMD. Global Retirement Partners LLC boosted its position in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the period. Indiana Trust & Investment Management Co purchased a new stake in shares of Revolution Medicines in the 4th quarter valued at $32,000. Torren Management LLC acquired a new position in Revolution Medicines during the 4th quarter worth about $33,000. Arax Advisory Partners acquired a new position in Revolution Medicines during the 4th quarter worth about $38,000. Finally, Darwin Wealth Management LLC acquired a new position in Revolution Medicines during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on RVMD. Jefferies Financial Group assumed coverage on Revolution Medicines in a research report on Monday, March 16th. They issued a “buy” rating on the stock. UBS Group started coverage on Revolution Medicines in a research report on Friday, February 27th. They set a “buy” rating for the company. Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Evercore reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $123.72.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.